Raymond James & Associates’s Lisata Therapeutics LSTA Stock Holding History

Raymond James & Associates’s Portfolio LSTA Stock Details LSTA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q3	–	Sell	-439	Closed	-$39K	–	3259
2016 Q2	$39K	Buy	439 +8	+2%	+$736	﹤0.01%	2894
2016 Q1	$48K	Buy	+431	New	+$42.3K	﹤0.01%	2788
2015 Q1	–	Sell	-442	Closed	-$250K	–	2371
2014 Q4	$250K	Buy	442 +4	+0.9%	+$2.72K	﹤0.01%	2174
2014 Q3	$363K	Hold	438	–	–	﹤0.01%	1966
2014 Q2	$428K	Buy	438 +3	+0.7%	+$2.92K	﹤0.01%	1911
2014 Q1	$460K	Buy	+435	New	+$472K	﹤0.01%	1818

Other funds holding LSTA

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

HCM

Hollencrest Capital Management Newport Beach, California $2.7B AUM 23.62% 1-Year Est. Return

KCM

Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

EGA

Eagle Global Advisors Houston, Texas $2.78B AUM 26.09% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

PAM

Panagora Asset Management Boston, Massachusetts $26.7B AUM 36.4% 1-Year Est. Return

Raymond James & Associates's LSTA Position: Q3 2016 in Review

Raymond James & Associates sold out of Lisata Therapeutics (LSTA) in Q3 2016, closing a stake of 439 shares — an estimated $39K sold.

Raymond James & Associates first reported a position in LSTA in Q1 2014 and held it in 6 quarters. The position peaked at $460K in Q1 2014. 28 funds tracked by Wall St. Rank hold LSTA as of Q3 2016.

Raymond James & Associates reported no remaining Lisata Therapeutics position as of Q3 2016 after selling out during the quarter.
Raymond James & Associates sold 439 Lisata Therapeutics shares in Q3 2016, an estimated $39K.
Raymond James & Associates first reported a position in Lisata Therapeutics in Q1 2014 and held it in 6 quarters.
Raymond James & Associates's Lisata Therapeutics position peaked at $460K in Q1 2014.
28 funds tracked by Wall St. Rank held Lisata Therapeutics as of Q3 2016.

Based on Raymond James & Associates's 13F filing for Q3 2016, filed 14 Nov 2016.